ZYMEWORKS INC. Proceeds from Common Stock Issued
ZYMEWORKS INC. (ZYME) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-02
- ZYMEWORKS INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- ZYMEWORKS INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- ZYMEWORKS INC. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00.
- ZYMEWORKS INC. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $0.00.
- ZYMEWORKS INC. proceeds from issuance of common stock for fiscal 2025 was $0.00.
- ZYMEWORKS INC. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ZYMEWORKS INC. proceeds from issuance of common stock for fiscal 2023 was $26.23M, a 75.60% decline from fiscal 2022.
- ZYMEWORKS INC. proceeds from issuance of common stock for fiscal 2022 was $107.53M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $26.23M derived: sum of 3 quarters · filed 2026-03-02 | $26.23M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $26.23M derived: sum of 2 quarters · filed 2024-10-31 | $26.23M 10-Q · filed 2024-10-31 | $26.23M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $26.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $26.23M 10-Q · filed 2024-08-01 | $26.23M derived: sum of 3 quarters · filed 2025-03-05 | $26.23M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | -$186.00K derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | -$186.00K derived: sum of 3 quarters · filed 2025-03-05 | $107.53M 10-K · filed 2025-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$186.00K derived: sum of 2 quarters · filed 2023-11-07 | $107.53M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $107.53M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $107.72M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 | |||
| 2020-12-31 | $300.91M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |